1 Reconciliation of Economic Arguments and Clinical Practice Monday November 4, 2002 ISPOR, Rotterdam Jan Busschbach PhD, –Department of Medical Psychology.

Slides:



Advertisements
Similar presentations
PERSONALIZED MEDICINE: Planning for the Future You, Your Biomarkers and Your Rights.
Advertisements

Quality of life (Utility) Measurements In Relation to Health Economics
Health and Human Sciences Economics and Health: a taster Masters in Public Health Key reference: McPake B., Kumaranayake, L. & Normand, C (2002) Health.
University of Sheffield [November/2013] School Of Health And Related.
COCOM Kwaliteit van leven in maat en getal Jan van Busschbach.
Justice and Economic Evaluation Prof. Dr. Jan Busschbach
1 The Future of Quality of Life Assessment in Cost-Effectiveness Research Prof. Jan J. v. Busschbach, Ph.D. Erasmus MC Medical Psychology and Psychotherapy.
1 The QALYs debate  Prof. dr. Jan J.V. Busschbach, Ph.D.  Erasmus MC  Institute for Medical Psychology and Psychotherapy.
1 Does it make a difference for the patient? Survival & Quality of life  Jan J. v. Busschbach, Ph.D.  Erasmus MC Institute for Medical Psychology and.
Balancing efficiency and equity in formal economic evaluation of health care. Erik Nord, Senior Researcher, Norwegian Institute of Public Health, Professor.
(Cost-)Effectiveness of Psychotherapy for Personality Disorders Jan van Busschbach Prof. Dr. J. van Busschbach Department of Medical Psychology and Psychotherapy.
“End-of-life expenses are shockingly high and widely variable”
1 Interactive Introduction cost effectiveness Jan J. v. Busschbach, Ph.D. Psychotherapeutic Centrum ‘De Viersprong’, Halsteren
A METHODOLOGY FOR MEASURING THE COST- UTILITY OF EARLY CHILDHOOD DEVELOPMENTAL INTERVENTIONS Quality of improved life opportunities (QILO)
1 Cost-Effectiveness in Medicine An Interactive Introduction  Jan J. v. Busschbach, Ph.D.  Erasmus MC Institute for Medical Psychology and Psychotherapy.
Developing a multi-criteria approach for drug reimbursement decision making: an initial step forward Francois Dionne- Centre for Clinical Epidemiology.
The relevance of Health Economics Research for the Health Policy Agenda Prof. Guillem López-Casasnovas Depart. de Economía Univ. Pompeu Fabra. Cataluña.
QALYs and Ethics Prof. dr. Jan van Busschbach 11.
Quality of life Assessment introduction
1 Dyslexia and Cost Effectiveness Prof. dr. Jan van Busschbach De Viersprong Erasmus MC.
1 EuroQol EQ-5D Jan J. V. Busschbach, Ph.D Psychotherapeutic Centrum ‘De Viersprong’, Halsteren Department of Medical.
QALYs and Ethics Is there an ethical / valid alternative?
1 Cost-effectiveness in Personality Disorder Dr. J.J.V. Busschbach Psychotherapeutic centre ‘De Viersprong’ –PO Box AA Halsteren
1 The valuation of disease-specific questionnaires for QALY analysis  To rescue data in absence of an utility measure  Growth hormone deficiency in adults.
Summary of measures of population Health Farid Najafi MD PhD School of Population Health Kermanshah University of Medical Sciences.
Rescuing Clinical Trial Data For Economic Evaluation
How can societal concerns for fairness be integrated in economic evaluations of health programs? Erik Nord, PhD, Senior Researcher, Norwegian Institute.
BACKGROUND Cost-effectiveness of Psychotherapy for Cluster C Personality Disorders and the Value of Information and Implementation Djøra I. Soeteman 1,2,
The return of the 5 year plan Mathematical programming for allocation of health care resources David Epstein, Karl Claxton, Mark Sculpher (CHE) Zaid Chalabi.
Economic evaluation of drugs for rare diseases CENTRE FOR HEALTH ECONOMICS K Claxton, C McCabe, A Tsuchiya Centre for Health Economics and Department of.
1 QALY, Burden of Disease and Budget Impact  Jan J.V. Busschbach, Ph.D.  Erasmus MC, Rotterdam, The Netherlands  
1 The valuation of disease-specific health states to facilitate economic evaluation E. Kok, E. Stolk, Jan J. v. Busschbach Address: –Jan v. Busschbach.
Cost-effectiveness of psychotherapy for personality disorders Djøra Soeteman Viersprong Institute for Studies on Personality Disorders Erasmus Medical.
Interactive Introduction cost effectiveness Jan J. v. Busschbach, Ph.D Viersprong Institute for studies on Personality Disorders (VISPD)
1 Cost effectiveness as argument for reimbursement in prevention Jan J. v. Busschbach, Ph.D. Erasmus MC –Institute for Medical Psychology and Psychotherapy.
1 Interactive introduction in Quality of life Assessment Jan J. v. Busschbach, Ph.D. Department of Medical Psychology and Psychotherapy, Erasmus MC
Copyright © 2006 Elsevier, Inc. All rights reserved Chapter 15 The Health Care Organization and Patterns of Nursing Care Delivery.
Economic evaluation of psychotherapy for personality disorders: burden of disease and cost-effectiveness Djøra Soeteman Viersprong Institute for Studies.
1 The Economic Burden of Personality Disorders  Djøra Soeteman, Jan J.V. Busschbach, Leona Hakkaart-van Roijen, Roel Verheul  Viersprong Institute for.
Quality of life and Cost-Effectiveness An Interactive Introduction Prof. Jan J. v. Busschbach, Ph.D. Erasmus MC Medical Psychology and Psychotherapy Viersprong.
11 Cost Effectiveness in Preventing Crime  Jan van Busschbach, Djøra Soeteman  Viersprong Institute for studies on Personality Disorders VISPD  Erasmus.
1 The Cost Effectiveness of Treatment of Personality Disorder  Dr. Jan J.V. Busschbach  PTC De Viersprong, Erasmus MC, Rotterdam, 
1 Scale recalibration effects in dementia patients and their proxies Sander Arons Dept. of Epidemiology, Biostatistics and HTA Radboud University Nijmegen.
Cost-effectiveness in the quest to convince the outside world Dr. Jan Busschbach De Viersprong Erasmus MC
1 Interactive Introduction Cost Effectiveness and Psychotherapy Jan J. v. Busschbach, Ph.D. Psychotherapeutic Centrum ‘De Viersprong’, Halsteren
1 The Economics of Health Care and New Technologies Friday October 18, 2002 Between Technology and Humanity, Brussels Jan Busschbach PhD, –Department of.
1 Value of Information in relation to risk management  Prof. Dr. Jan J.V. Busschbach.
“Introduction to Patient Preference Methods used for QALYs” Presented by: Jan Busschbach, PhD, Chair Section Medical Psychology and Psychotherapy, Department.
Taxation Frederick University 2009.
Values Lower Than Death Jan J. v. Busschbach, Ph.D. –Erasmus University Rotterdam institute for Medical Technology Assessment (iMTA) PO box DR.
How to weight cost effectiveness in appraisal NVTAG / CVZ course: The appraisal process, work in progress 22th of April 2009 Jan van Busschbach.
(Cost-)Effectiveness of Psychotherapy for Personality Disorders Jan van Busschbach Prof. Dr. J. van Busschbach Department of Medical Psychology and Psychotherapy.
1 Quality of life and Cost-Effectiveness An Interactive Introduction Prof. Jan J. v. Busschbach, Ph.D. Erasmus MC Medical Psychology and Psychotherapy.
1 Are values cultural determined…..  Many believe that QoL is cultural determined  One of the starting points of the EuroQol group.
Measures of the health status of Australians. Sources of health data and statistics in Australia Australian Bureau of Statistics (ABS), Australia’s national.
© University of South Wales Royal College of Speech and Language Therapists Outcomes Conference and Hub Launch Belfast, May 1, 2014 Running a tight ship:
The determinants of change in the cost-effectiveness threshold Mike Paulden, MSc 1 James O’Mahony, PhD 2 Christopher McCabe, PhD 1 1 Department of Emergency.
1 Cost-Effectiveness in Medicine An Interactive Introduction  Jan J. v. Busschbach, Ph.D.  Erasmus MC Institute for Medical Psychology and Psychotherapy.
Inquiry Day – Healthy Staffordshire Select Committee 25 November 2015.
Medical Necessity Criteria An Overview of Key Components Presented by BHM Healthcare Solutions.
The burden of disease in patients with personality disorder indicated for psychotherapy: Arguments for necessity of care Djøra Soeteman, MSc
Measures of the health status of Australians
Cost effectiveness Analysis: Valuing Health; Valuing Research!
Global burden of diseases
How much does the U.S. spend to treat different diseases?
AGEING AND OLDAGE in HISTORY .
The valuation of disease-specific questionnaires for QALY analysis
Why do/should we do economic evaluation?
Ethics in Research.
Justification treatment cost
Presentation transcript:

1 Reconciliation of Economic Arguments and Clinical Practice Monday November 4, 2002 ISPOR, Rotterdam Jan Busschbach PhD, –Department of Medical Psychology and Psychotherapy, Erasmus MC –Psychotherapeutic Centrum ‘De Viersprong’ Elly Stolk, Marten Poley, Werner Brouwer –institute for Medical Technology Assessment (iMTA), Erasmus University

2 Medical Technology Assessment A combination of arguments –Health economic –Juridical –Social –Ethical What are these other arguments? –Are they important? –How can we use them?

3 Ad hoc arguments If economics evaluation fails –Reimbursement of lung transplantation –No reimbursement of Viagra First, debate about the validity of the health economics –lung transplantation: not all cost of screening / waiting list should be included –Viagra: preferences for sex (erectile functioning) can not be measured Secondly, ad hoc arguments are used –lung transplantation: it is unethical to let someone die –Viagra: erectile dysfunction in old men is not a disease

4 Ad hoc argument repressed equity concerns Severity of illness –Looking forwards »Prospective health –lung transplantation: it is unethical to let someone die »Rule of rescue »Necessity of care »Eric Nord Faire innings –Looking backwards »Total health –Viagra: when you get older, erectile dysfunction is not longer considered a disease »Alan Williams

5 Person trade-off Incorporates equity concerns in QALY –Nord / Richardson / Murray ?? persons 1 year free from disease Q 100 persons additionally 1 healthy year

6 PTO elicits extreme values

7 Psychometrics Paul Kind If we look at TTO and PTO... –we see that one of them is wrong If we look at PTO alone... –We still see that one of them is wrong... PTO is not a quick fix

8 Incorporated equity in model Weight QALY by equity –Wagstaff 1991 –Equity-efficiency trade-off Dunning’s Funnel –1990 –Government declaration 2002 –Necessary care »Need »Equity elements –Efficacy –Cost effectiveness –Own account and responsibility

9 Funnel suggest no interaction The criteria are called sieve –Dutch: “zeven” –An intervention passes the sieve or it stays on top –“Only after the health care intervention has passed the sieve, the next criterion is applied.” »Stronks, 1995 The suggestion is wrong –Dunning 2002 –The funnel is an interactive model »Necessary care (equity) interacts with (cost) effectiveness

10 Several definition of equity Severity of illness –How bad is it now? Fair innings –How good has it been? Necessary care –Is this a normal life? But what if the severity of illness is a result of old age? Discriminate the old? How do we define “a normal life”

11 Compares loss in QALY with expected QALY –The higher the proportion –The higher the need for equity compensation Proportional short fall Prop. Short Fall = 25%Prop. Short Fall = 50%Prop. Short Fall = 60% QALY lostQALY gain t  QoL  Prop. Short Fall = 50% Now

12 Proportional short fall Intermediate position Severity of illness –Looking forwards –Prospective health Fair innings –Looking backwards –Total health Proportional short fall –Intermediate Total health patient A t  B Prospective health patient A B Birth Now

13 What can we do with it? Better understand health policy –Why are some cost effective treatments not reimbursed –Why are some not cost effective treatment reimbursed Cost effectiveness interact with equity –Is there indeed a shifting threshold? –Tested in policy practice

14 A shifting threshold

15 Practice

16 CE-ratio by equity

17 Efficiency / Equity trade-off The more severe the health state –The more we are willing to contribute –The more money we are willing the spend –We accept a high cost per QALY Ad the price of a lower average level of health in the population –We reduce variance at the price of lower average health in the population

18 Implication Ethics can be measured Makes health care policy more understandable –Reimbursement of lung transplantation »Bad cost effectiveness, high burden –No reimbursement of Viagra »Good cost effectiveness, low burden Explains the existence of burden of disease studies